2024³â 12¿ù 25ÀÏ ¼ö¿äÀÏ
 
 
  ÇöÀçÀ§Ä¡ > ´º½ºÁö´åÄÄ > Science & Technology

·£¼¶¿þ¾îºÎÅÍ µÅÁöµµ»ì±îÁö... ³ë·ÃÇØÁø »ç±âÇà°¢

 

Á¤Ä¡

 

°æÁ¦

 

»çȸ

 

»ýÈ°

 

¹®È­

 

±¹Á¦

 

°úÇбâ¼ú

 

¿¬¿¹

 

½ºÆ÷Ã÷

 

ÀÚµ¿Â÷

 

ºÎµ¿»ê

 

°æ¿µ

 

¿µ¾÷

 

¹Ìµð¾î

 

½Å»óÇ°

 

±³À°

 

ÇÐȸ

 

½Å°£

 

°øÁö»çÇ×

 

Ä®·³

 

Ä·ÆäÀÎ
Çѻ츲 ¡®¿ì¸®´Â ÇѽҸ²¡¯ ½Ò ¼Òºñ Ä·ÆäÀÎ ½Ã...
1000¸¸¿øÂ¥¸® Àΰø¿Í¿ì, °Ç°­º¸Çè Áö¿ø ¡®Æò...
- - - - - - -
 

Japan¡¯s First Discovery1 on Visceral Fat and Immune Activity in Joint Research by Kirin Holdings and Kao

´º½ºÀÏÀÚ: 2023-11-26

TOKYO -- Kirin Holdings Company, Limited (TOKYO:2503) and Kao Corporation (TOKYO:4452) will participate in the Wakayama Health Promotion Study, a cohort study*2 led by Wakayama Medical University and organized by the Health Promotion Research Center (HPRC), a non-profit organization. Kao and Kirin Holdings conducted a joint study from November 2022 to investigate the relationship between visceral fat and the plasmacytoid dendritic cells (pDC*3) activity*4, which are the command center for immunity.

In recent years, attention has focused on the relationship between obesity and immunity, as it has been reported that obesity leads to more severe viral infections*5. This study was the first in Japan*1 to investigate the relationship between visceral fat and immune activity and confirm that high visceral fat levels are associated with low pDC activity (low immune function) and that high visceral fat levels and low pDC activity are associated with a high risk of contracting novel coronavirus infection and influenza. These findings have not yet been reported in any paper in the world*6. The results will be presented at the 44th Annual Meeting of the Japan Society for the Study of Obesity and the 41st Annual Meeting of the Japanese Society for Treatment of Obesity, which will be held in Miyagi Prefecture, on November 25 (Sat.) and 26 (Sun.), 2023.

*1 Based on article and abstract information published in Pubmed and the Journal of Health Care and Society Web (as of November 22, 2023, according to KnowledgeWire)
*2 One of the observational research methods in analytical epidemiology. By creating groups involved in specific disease factors and uninvolved groups, and calculating the incidence rate of the target disease within each group, it is possible to examine the relation between the disease factors and the onset.
*3 An immune cell that plays an important role as a command post when bacteria or viruses enter the body. Activation of pDC activates various immune cells such as NK cells, T cells, and B cells to protect against viral infection.
*4 Percentage of pDCs producing antiviral factors upon stimulation that mimics viral infection
*5 Ghilotti F et al. J Epidemiol. 2019; 48(6): 1783-1794.
Popkin BM et al. Obes Rev. 2020; 21(11): e13128.
*6 Based on article information published in Pubmed and the Journal of Health Care and Society Web (as of November 22, 2023, according to KnowledgeWire)

Joint Research Results (Summary)

Japan’s First Discovery*1
(1) Lower pDC activity was observed in individuals with high visceral fat.
(2) A higher percentage of people with high visceral fat and low pDC activity had contracted novel coronavirus infection and influenza compared to those who did not.

Implications Obtained
It is suggested that maintaining low visceral fat mass and high pDC activity is associated with a reduced risk of contracting novel coronavirus infection and influenza.

Joint Research Results

- Background and Objectives


Obesity is defined by the World Health Organization (WHO) as “a condition of increased health risk due to abnormal or excessive fat accumulation” and is associated with an increased risk of chronic diseases. The effects of obesity on health have been studied in many countries. In recent years, the relationship between obesity and immunity has been attracting attention, as it has been reported that obesity leads to more severe viral infections*7.

This research was conducted as part of the Wakayama Health Promotion Study, which has targeted residents of Wakayama Prefecture since 2011. Kao, which has long been involved in research on visceral fat obesity, which is considered closely related to lifestyle-related diseases, and Kirin Holdings, which has been conducting research in the field of immunology for over 35 years, collaborated to clarify the relationship between visceral fat and pDC activity.
*7 Pranata R et al. Clin Nutr ESPEN. 2021; 43: 163-168.

- What is the Wakayama Health Promotion Study?

This is a cohort study led by Wakayama Medical University since 2011 which is currently being conducted in collaboration with HPRC, to identify genetic and environmental factors involved in the development of various diseases among local residents in Wakayama Prefecture.

Much research has been done in the program to date on lifestyle, lifestyle-related diseases, and muscle mass, resulting in many findings including the relationship between loss of muscle mass and the development of atherosclerosis and the relationship between a history of falls and voluntary physical activity. This was the first time the program conducted research into the immune function.

Through the Wakayama Health Promotion Study, Kirin Holdings and Kao are working to clarify the relationship between visceral fat mass and pDC activity in an effort to reduce health risks for consumers in the future.

- Research Methods


In November 2022, specific checkups were conducted in Wakayama Prefecture of 223 residents aged 50-55. From this, Kao obtained data on lifestyle habits and visceral fat area, while Kirin measured data on pDC activity in the blood. These data were shared among the two teams, and the relationship between visceral fat and pDC activity was jointly studied and analyzed. The groups studied were divided as follows.

Visceral fat area: Based on a median value of 77 cm2 for all subjects, those with visceral fat less than 77 cm2 were defined as the low visceral fat group, and those with visceral fat greater than 77 cm2 as the high visceral fat group.

pDC activity: Based on a median value of 9.52% for all subjects, those with pDC activity of 9.52% or less were defined as the low pDC activity group, and those with pDC activity of 9.52% or more were defined as the high pDC activity group.

- Results


Result 1: Relationship between visceral fat area and pDC activity
The group with higher visceral fat area values had significantly lower pDC activity than the group with lower visceral fat area values (Figure 1).

Result 2: Effect of visceral fat area and pDC activity on the contracting of infectious diseases
The group with high visceral fat area values had a higher incidence of novel coronavirus infection than the group with low values, with a 7-fold higher odds ratio*8. Meanwhile, the group with low pDC activity had a higher incidence of novel coronavirus infection than the group with high pDC activity, with a 5-fold higher odds ratio (Figure 2).

The analysis was also divided into four groups to confirm the synergistic effect of high or low visceral fat area and pDC activity and found that the group with high visceral fat area and low pDC activity had a higher incidence of novel coronavirus infection than the group with low visceral fat area and high pDC activity, with a 20-fold higher odds ratio. Similar results were observed with influenza (Figure 3).
*8 The odds ratio is a value used to express the likelihood of an event. The odds ratio and likelihood of occurrence are positively correlated.

- Collaborative Research Results

For the first time in the world, this collaboration found that people with high visceral fat area levels had low pDC activity. It was also suggested that visceral fat area and pDC activity, respectively, affect susceptibility to novel coronavirus infection and influenza, and that people with high visceral fat area and low pDC activity are particularly susceptible to these diseases.

Thus, it can be said that it is important for people with high visceral fat area values and low pDC activity to address both visceral fat mass and immune function.



 Àüü´º½º¸ñ·ÏÀ¸·Î

Novotech Named a Fierce CRO Award Winner in the Excellence
SINOVAC Initiated a Phase III Clinical Trial on Bivalent Vaccine Against Hand Foot and Mouth Disease (HFMD)
The Next Gen of AI Awaits, GIGABYTE Sets the Benchmark for HPC at CES 2025
SpaceRISE Signs Concession Contract to Deliver Europe¡¯s IRIS©÷ Connectivity Network
Boomi Boosts Data Management Capabilities With Acquisition of Modern Data Integration Provider Rivery
Korean Robotaxi Startup Sonnet.AI Secures Level 4 Autonomous Shuttles Certification
KIOXIA NVMe SSD Cryptographic Module Achieves FIPS 140-3 Level 2 Validation

 

CHMP Recommends Approval of Galderma¡¯s Nemolizumab for Moderate-to-Se...
BrightPath Bio and Cellistic Announced Process Development and Manufac...
Parse Biosciences Launches Evercode Mouse BCR to Support Antibody Engi...
PDC*line Pharma Presents Primary Clinical Results From Phase I/II Tria...
Tanner Pharma Expands Global Access to Botensilimab and Balstilimab Th...
Abu Dhabi¡¯s Technology Innovation Institute Inaugurates Open-Source A...
DNP Achieves Fine Pattern Resolution on EUV Lithography Photomasks for...

 


°øÁö»çÇ×
´º½ºÁö ÇÑÀÚÇ¥±â 'ãæÚ¤ó¢'
´º½º±×·ì Á¤º¸ ¹Ìµð¾î ºÎ¹® »óÇ¥µî·Ï
¾ËÇÁ·Ò °è¿­ »óÇ¥, »óÇ¥µî·Ï ¿Ï·á
¾Ë¶ã°Ç¼³, »óÇ¥µî·Ï ¿Ï·á
Á¸Â÷´åÄÄ, ±Û²Ã º¯°æ »óÇ¥µî·Ï ¿Ï·á

 

ȸ»ç¼Ò°³ | ÀÎÀçä¿ë | ÀÌ¿ë¾à°ü | °³ÀÎÁ¤º¸Ãë±Þ¹æħ | û¼Ò³âº¸È£Á¤Ã¥ | Ã¥ÀÓÇÑ°è¿Í ¹ýÀû°íÁö | À̸ÞÀÏÁÖ¼Ò¹«´Ü¼öÁý°ÅºÎ | °í°´¼¾ÅÍ

±â»çÁ¦º¸ À̸ÞÀÏ news@newsji.com, ÀüÈ­ 050 2222 0002, Æѽº 050 2222 0111, ÁÖ¼Ò : ¼­¿ï ±¸·Î±¸ °¡¸¶»ê·Î 27±æ 60 1-37È£

ÀÎÅͳݴº½º¼­ºñ½º»ç¾÷µî·Ï : ¼­¿ï ÀÚ00447, µî·ÏÀÏÀÚ : 2013.12.23., ´º½º¹è¿­ ¹× û¼Ò³âº¸È£ÀÇ Ã¥ÀÓ : ´ëÇ¥ CEO

Copyright ¨Ï All rights reserved..